--- title: "Neuphoria Therapeutics gets Nasdaq extension to December 29" url: "https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-extension-december-29-2025-hold/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-09-16" section: "Listings" tickers: "NASDAQ:NEUP" source: "https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/ea0257502-8k_neuphoria.htm" summary: "Nasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December" --- By the aibio.space news desk. Sources - [Neuphoria Therapeutics Inc. Form 8-K filed September 16, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/ea0257502-8k_neuphoria.htm) - [Neuphoria Therapeutics Inc. Form 10-K filed September 30, 2024: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1191070/000121390024082909/ea0213573-10k_bionomic.htm) [NEUP](https://aibio.space/companies/neuphoria-therapeutics/) 2025-09-16 # Neuphoria Therapeutics gets Nasdaq extension to December 29, 2025 to hold annual meeting Tickers [NEUP](https://aibio.space/companies/neuphoria-therapeutics/) Nasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025. ## Key facts - **Company**: Neuphoria Therapeutics Inc. (NASDAQ: NEUP) - **News type**: Listings - **Primary source**: [Neuphoria Therapeutics Inc. Form 8-K filed September 16, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/ea0257502-8k_neuphoria.htm) *Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.* Neuphoria Therapeutics Inc. (Nasdaq: [NEUP](https://aibio.space/companies/neuphoria-therapeutics/)) said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/ea0257502-8k_neuphoria.htm) that Nasdaq has accepted its plan to regain compliance with the exchange's annual meeting rule and has given it until December 29, 2025 to hold the meeting. The company was already out of compliance. It had not held an annual general meeting of stockholders within twelve months of the end of its fiscal year ended June 30, 2024. ## The deficiency and the extension On July 18, 2025, Neuphoria received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The letter said the company did not meet Nasdaq Listing Rule 5620(a), which requires a Nasdaq-listed company to hold an annual meeting of shareholders no later than one year after the end of its fiscal year. The company says it submitted its plan to regain compliance on time. On September 10, 2025, Nasdaq told the company it had accepted the plan and granted an extension of 180 calendar days from the end of the company's fiscal year, or until December 29, 2025. The 8-K calls this the Compliance Period. ## What the company says it will do Neuphoria says it intends to file its annual report on Form 10-K on or before September 29, 2025. It then intends to file a proxy statement and notice of meeting for its 2025 annual general shareholder meeting on time, and to hold the meeting within the Compliance Period. The 8-K does not say why the annual meeting was missed, and it gives no meeting date. Chief Executive Officer Spyridon Papapetropoulos signed the 8-K on September 16, 2025. ## The company and its lead drug The company is a Delaware corporation based in Burlington, Massachusetts. Its annual report in the record was filed on September 30, 2024 under the name Bionomics Limited, an Australian company incorporated in 1996 that began reporting as a US domestic filer on July 1, 2024. In it the company describes itself as a clinical-stage biopharmaceutical company developing allosteric ion channel modulators for serious central nervous system disorders. Its lead candidate is BNC210, an oral negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which it is developing for the chronic treatment of post-traumatic stress disorder (PTSD) and the acute treatment of social anxiety disorder (SAD). ## The trial record the company cites In September 2023 the company announced results of the Phase 2b ATTUNE study, run at 34 sites in the United States and the United Kingdom. It enrolled 212 patients, who received 900 mg of BNC210 twice daily or placebo for 12 weeks, with 106 in each group. The company says the trial met its primary endpoint, the change in the CAPS-5 total symptom severity score from baseline to Week 12 (p=0.048). That is a statistically significant result but not by a wide margin, from a single mid-stage trial. In July 2024 the company announced a positive outcome of an End-of-Phase 2 meeting with the FDA. It says that meeting leaves a path to a New Drug Application for PTSD that, alongside ATTUNE, includes one additional Phase 3 trial testing two dose levels for 12 weeks with a 52-week open-label extension. The company planned to start that trial in the second half of 2025, "contingent upon having sufficient capital on hand." The FDA denied its initial Breakthrough Therapy designation application. The company says it is considering a rebuttal and holds Fast Track designation for the PTSD and SAD programs. The social anxiety record is weaker. The Phase 2 PREVAIL trial, with topline data in December 2022, narrowly missed its primary endpoint, a measure of distress during a public speaking challenge. A Phase 3 trial called AFFIRM-1 began patient screening in July 2024, targeting 330 adults who receive a single 225 mg dose of BNC210 or placebo about one hour before speaking in public. The annual report expected topline results in the third quarter of 2025. The 8-K gives no update on that trial. ## What comes next The next dates are September 29, 2025 for the 10-K and December 29, 2025 for the annual meeting. The 8-K does not describe what happens if the deadline is missed. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story NEUP Neuphoria Therapeutics Inc. NASDAQ · United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-extension-december-29-2025-hold/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Neuphoria Therapeutics gets Nasdaq extension to December 29", 2025-09-16, https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-extension-december-29-2025-hold/